Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00162942 · ClinicalTrials.gov registry record · Phase 3
Study for the Treatment of Crohn's Disease With Adacolumn
A Phase 3 study of Crohn's Disease, sponsored by Otsuka America Pharmaceutical.
- Completed
- Registry status
- Phase 3
- Development phase
- 235
- Enrollment target
- 20
- Study locations
NCT00162942 is a Phase 3 study of Crohn's Disease that has completed, run by Otsuka America Pharmaceutical. The registered enrollment target is 235 participants, below the 2,392-participant average among 105 other Crohn's Disease trials with a reported enrollment target (90% lower). The trial reports 20 study locations across 15 states.
The verdict
NCT00162942, a Phase 3 study of Crohn's Disease, has completed, sponsored by Otsuka America Pharmaceutical.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 235 participants
- Enrollment target
- 20
- Study locations
Study Summary
The purpose of this study is to evaluate the safety and effectiveness of the Adacolumn Apheresis System as a treatment for the signs and symptoms of Crohn's disease.
Conditions Studied
Interventions
- DEVICE Sham
- DEVICE Adacolumn
Study Locations (20)
California
- Capitol Gastroenterology Consultants Medical Group - Roseville
- UCSF Mount Zion Medical Center - San Francisco
Maryland
- Johns Hopkins University - Baltimore
- Metropolitan Gastroenterology Group - Chevy Chase
Michigan
- University of Michigan - Ann Arbor
- Clinical Research Institute of Michigan - Clinton Township
North Carolina
- University of North Carolina, Division of Digestive Disease & Nutrition - Chapel Hill
- Duke University Medical Center - Durham
Ohio
- Consultants for Clinical Research - Cincinnati
- Cleveland Clinic Foundation - Cleveland
Arizona
- Mayo Clinic Scottsdale - Phoenix
Colorado
- Rocky Mountain Gastroenterology Associates, PC - Wheat Ridge
Connecticut
- Medical Research Institute of Connecticut - Hamden
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 235 participants |
| Start Date | 2005-01 |
| Est. Completion | 2007-12 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00162942
The ClinicalTrials.gov registry entry for NCT00162942 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 235 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 2,392-participant average among 105 other Crohn's Disease trials with a reported enrollment target (90% lower). The listed sponsor is Otsuka America Pharmaceutical, which has 10 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Crohn's Disease appearing as the primary indexed condition, and to 2 interventions - of which Sham is the first listed.
NCT00162942 reports 20 study locations spanning 15 distinct geographic areas - top geographies include California, Maryland, Michigan.
Frequently Asked Questions
What is clinical trial NCT00162942 about?
NCT00162942 is a clinical study titled "Study for the Treatment of Crohn's Disease With Adacolumn". The purpose of this study is to evaluate the safety and effectiveness of the Adacolumn Apheresis System as a treatment for the signs and symptoms of Crohn's disease.
What is the current status of trial NCT00162942?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 235 participants. The study started on 2005-01. Estimated completion is 2007-12.
What conditions does trial NCT00162942 study?
This clinical trial studies the following conditions: Crohn's Disease.
What interventions are being tested in trial NCT00162942?
The interventions under investigation include: Sham (DEVICE), Adacolumn (DEVICE).
Who is sponsoring clinical trial NCT00162942?
This trial is sponsored by Otsuka America Pharmaceutical, which has 10 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00162942 being conducted?
This trial has 20 study locations across Arizona, California, Colorado, Connecticut, Florida. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Crohn's Disease
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Testing the Role of Anti-fungal Therapy in Improving the Response to Therapies for Crohn's Disease
RECRUITING · Phase 3
-
Transmural Healing and Disease-Modifying Effect of Guselkumab in Crohn's Disease Patients
RECRUITING · Phase 3
-
A Study of Mirikizumab (LY3074828) in Pediatric Participants With Crohn's Disease
RECRUITING · Phase 3
-
An Induction Study to Investigate the Efficacy and Safety of Duvakitug in Participants With Moderately to Severely Active Crohn's Disease
RECRUITING · Phase 3
-
A Study of Vedolizumab With and Without Upadacitinib in Adults With Crohn's Disease
RECRUITING · Phase 3
-
A Study of Guselkumab in Pediatric Participants With Moderately to Severely Active Crohn's Disease
RECRUITING · Phase 3
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.